Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient

被引：7
|
作者：
Ito, Munehiro [1 ]
Kanda, Shintaro [1 ]
Yoshida, Tatsuya [1 ]
Okuma, Yusuke [1 ]
Jo, Hitomi [1 ]
Fukuhara, Suguru [2 ]
Maeshima, Akiko Miyagi [3 ]
Ohe, Yuichiro [1 ]
机构：
[1] Natl Canc Ctr, Dept Thorac Oncol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan
[2] Natl Canc Ctr, Dept Hematol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan
[3] Natl Canc Ctr, Dept Diagnost Pathol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan
来源：
LUNG CANCER | 2020年 / 146卷
关键词：
immune-related thrombocytopenia; pembrolizumab; eltrombopag olamine; rituximab; non-small cell lung cancer; PURPURA;
D O I：
10.1016/j.lungcan.2020.05.015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Objectives: Immune checkpoint inhibitors (ICIs) have shown antitumor activity against a wide variety of malignancies. ICI-induced immune-related thrombocytopenia is a rare immune-related adverse event (irAE). Little is known about the treatment of refractory immune-related thrombocytopenia in non-small cell lung cancer (NSCLC) patients treated with pembrolizumab. Results: We report the case of a patient with advanced NSCLC complicated by pembrolizumab-induced refractory immune-related thrombocytopenia who showed remarkable improvement in the thrombocytopenia in response to eltrombopag olamine treatment. Conclusion: Eltrombopag olamine can be a viable treatment option for refractory pembrolizumab-induced immune-related thrombocytopenia in an NSCLC patient.
引用
收藏
页码：362 / 365
页数：4
相关论文
共 50 条
  • [1] Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer
    Nakamura, Masakatsu
    Otsuka, Toshimi
    Hayashi, Ranji
    Horita, Tomoe
    Ota, Masafumi
    Sakurai, Naoko
    Takano, Hikaru
    Hayashi, Tasuku
    Kumagai, Motona
    Yamada, Sohsuke
    Arisawa, Tomiyasu
    INTERNAL MEDICINE, 2020, 59 (21) : 2711 - 2717
  • [2] Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer
    Mori, Hidenori
    Sakai, Chizuru
    Iwai, Masamichi
    Sasaki, Yuka
    Gomyo, Takenobu
    Toyoshi, Sayaka
    Kaito, Daizo
    Yanase, Komei
    Ito, Fumitaka
    Endo, Junki
    Funaguchi, Norihiko
    Ohno, Yasushi
    Minatoguchi, Shinya
    RESPIRATORY MEDICINE CASE REPORTS, 2019, 28
  • [3] Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient
    Karakas, Yusuf
    Yuce, Deniz
    Kilickap, Saadettin
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (10) : 621 - +
  • [4] Steroid-Refractory Immune-Related Hepatitis Caused by Pembrolizumab with Stage IVB Non-Small Cell Lung Cancer: A Case Report
    Hamaguchi, Tomomi
    Ueno, Makoto
    Kobayashi, Satoshi
    Tezuka, Shun
    Morimoto, Manabu
    Kato, Terufumi
    Saito, Haruhiro
    Sato, Shinya
    Furuse, Junji
    Maeda, Shin
    CASE REPORTS IN GASTROENTEROLOGY, 2025, 19 (01) : 14 - 21
  • [5] Predictive value of immune-related adverse events during pembrolizumab treatment in non-small cell lung cancer
    Valencia Soto, Carmen Maria
    Villacanas Palomares, Maria Victoria
    Garcia-Avello Fernandez-Cueto, Adela
    Barbadillo Villanueva, Sara
    Martinez Callejo, Virginia
    Ochagavia Sufrategui, Maria
    Munoz Cacho, Pedro
    Valero Dominguez, Marta
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2024, 31 (01) : 40 - 45
  • [6] Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
    Noguchi, Susumu
    Suminaga, Keiichiro
    Kaki, Takahiro
    Kawachi, Hiroaki
    Fukao, Akari
    Terashita, Satoshi
    Horikawa, Sadao
    Ikeue, Tatsuyoshi
    Sugita, Takakazu
    LUNG CANCER-TARGETS AND THERAPY, 2020, 11 : 53 - 57
  • [7] Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer
    Yasuda, Yuichiro
    Urata, Yoshiko
    Tohnai, Rie
    Ito, Shoichi
    Kawa, Yoshitaka
    Kono, Yuko
    Hattori, Yoshihiro
    Tsuda, Masahiro
    Sakuma, Toshiko
    Negoro, Shunichi
    Satouchi, Miyako
    INTERNAL MEDICINE, 2018, 57 (09) : 1269 - 1272
  • [8] PEMBROLIZUMAB-INDUCED HYPERPROGRESSION IN PATIENT WITH NON-SMALL CELL LUNG CANCER
    Mandal, Shobha
    Poulose, Joyson
    Sulaiman, Layla
    Kasireddy, Vineela
    CHEST, 2020, 158 (04) : 1536A - 1536A
  • [9] Immune-related thyroid dysfunction in patients with non-small cell lung cancer
    Cai, Cuihong
    Zhou, Shuangshuang
    Qu, Jingjing
    Zhou, Jianying
    JOURNAL OF THORACIC DISEASE, 2024, 16 (01) : 253 - 263
  • [10] Association between immune-related dermatologic adverse events and efficacy of pembrolizumab in non-small cell lung cancer patients
    Fukuoka, T.
    Yamamoto, Y.
    Utsunomiya, J.
    Usami, E.
    Kimura, M.
    Yoshimura, T.
    Nakamura, M.
    Toda, Y.
    PHARMAZIE, 2021, 76 (05): : 239 - 242
12345